The U.S. Food and Drug Administration approved Gilead’s remdesivir under Emergency Use Authorization as a treatment for COVID-19 following reports the drug met the primary endpoint in a U.S. National Institute of Allergy and Infectious Diseases (NIAID) clinical trial.
Gilead Sciences – which manufactures remdesivir – is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once the medicine is approved, Chief Executive Daniel O’Day said.
Gilead Sciences Inc., maker of the closely watched experimental coronavirus drug remdesivir, said the company will work with international partners to expand production of the potential COVID-19 treatment.
At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.
U.S. President Donald Trump said the United States plans to accelerate the development of a coronavirus vaccine, an effort that has been dubbed “Operation Warp Speed.”
The U.S. Food and Drug Administration is working at “lightning speed” to review data on Gilead Sciences Inc.’s experimental antiviral drug remdesivir in treating COVID-19 disease, the head of the agency told Bloomberg in an interview.
Gilead Sciences Inc.’s experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, and the company provided data suggesting the medicine worked better when given earlier in the course of infection.
Although not official and largely anecdotal, there are early signs that Gilead Sciences’ experimental antiviral drug remdesivir is effective in treating COVID-19.
Shares of Gilead Sciences Inc. rose 10 percent after a report that patients with COVID-19 treated with the company’s experimental drug, remdesivir, in a clinical trial showed rapid recovery in fever and respiratory symptoms.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.